Use of statins and angiotensin converting enzyme inhibitors (ACE-Is) and the risk of age-related macular degeneration: Nested case-control study

Current Drug Safety

Volumn 3, Issue 1, 2008, Pages 24-26

  Etminan, Mahyar ^a   Brophy, James M ^b   Maberley, David ^c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Case control studies; HMG CoA reductase Inhibitors; Lipid lowering agents; Macular degeneration; Statins

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; CANADA; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK ASSESSMENT;

AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACULAR DEGENERATION; MALE; QUEBEC; RISK ASSESSMENT;

EID: 38949137323     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488608783333952     Document Type: Review

References (17)

1. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 1977; 106(1): 17-32.
2. CNIB. Spotlight on AMD. http://www.cnib.ca/vision-health/vision-loss/ amd/index.html. In: Canadian National Istitute for the Blind.; 2006.
3. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006; 58(3): 353-63.
4. Schaumberg DA, Christen WG, Buring JE, Glynn RJ, Rifai N, Ridker PM. High sensitivity, C-reactive. protein, other markers of inflammation ad the incidence of macular degeneration in women. Arch Opthalmol 2007; 125: 3005.
5. Smith BT, Joseph DP, Grand MG. Treatment of neovascular age-related macular degeneration: past, present and future directions. Curr Opinion Opthal 2007; 18: 240-4.
6. Vortuba M, Gregor Z. Neovascular age-related macular degeneration: present and future treatment options. Eye 2001; 15: 424-9.
7. Schaumberg DA, Christen WG, Buring JE, Glynn RJ, Rifai N, Ridker PM. High sensitivity C-reactive protein, other markers of inflammation ad the incidence of macular degeneration in women. Arch Opthalmol 2007; 125: 3005.
8. van Leeuwen R, Boekhoorn S, Vingereling JR, Witteman JC, Klaver CC, Hofman A. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005; 294: 310-7.
9. McGwin G, Jr., Owsley C, Curcio CA, et al. The association between statin use and age related maculopathy. Br J Ophthalmol 2003. 87(9): 1121-1125.
10. Klein R, Klein BE, Jensen SC, et al. Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2001; 119(9): 1354-1359.
11. Ferder L, Inserra F, Martinez-Maldonado M. Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr Hypertens Rep 2006; 8: 191-8.
12. Levy AR, Tamblyn RM, Fitchett D, McLeod PJ, Hanley JA. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol 1999; 15: 1277-82.
13. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999-1009.
14. Brophy JM, Bourgault C, Brassard P. The use of cholesterol-lowering medications aftercoronary revascularization. CMAJ 2003; 169: 1153-7.
15. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-60.
16. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137: 486-495.
17. van Leeuwen R, Vingerling JR, Hofman A, et al. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003; 326(7383): 255-256.